Immunopotentiators in Modern Vaccines

7-9 May 2014, Sao Rafael Atlantic Hotel, Albufeira, Algarve, Portugal

  • Increase font size
  • Default font size
  • Decrease font size


The IMV conference series offers a regular update on the developments/issues surrounding ‘immunopotentiators for modern vaccines’ and is a vital aspect of the growth of this important area of vaccinology.

IMV 2014 will once again offer an international forum to review the current state of research and developments/applications of immunopotentiators/adjuvants for modern vaccines and associated vaccine programmes/strategies. IMV 2014 will be of interest to researchers involved in determining the mechanisms of adjuvant function and responses and optimising these responses, manufacturers of biologicals, those involved in the manufacture/licensing of injectable biologicals, and those interested in the control of infectious and non/infectious diseases.

Scientific Advisory Panel/Moderators

Conference Co-Chairmen:
Virgil Schijns (Wageningen University, Wageningen, The Netherlands) and Jim Brewer (University of Glasgow, UK)

Derek O’Hagan (Novartis Vaccines, USA)
Gwyn Davies (St. George’s University of London, UK)
Martin Bachmann (University of Zurich, Zurich, Switzerland)
Adriana Baz Morelli (CSL Limited, Australia)
Ali Harandi (Gothenburg University, Sweden)
Rob Lambkin-Williams (Retroscreen Virology, London, UK)
Nathalie Garcon (GSK Biologicals, Rixensart, Belgium)
Geert Vanden Bossche (UNIVAC LLC, Belgium)
Steve Reed (IDRI, Seattle, Washington, USA)
Heather Davis (Pfizer Vaccines Research, Ottawa, Canada)
Dennis Christensen (Statens Serum Institut, Copenhagen, Denmark)
Niranjan Sardesai (INOVIO Inc., Blue Bell, Pennsylvania, USA)

Conference Sessions

IMV 2014 will include the following topics:

  • Immunological mechanisms underlying adjuvant activity (signal 1,2,3 adjuvants)
  • Adjuvant developments
  • Vaccine developments
  • Host-derived immunopotentiators (cytokines, DCs, IFNs. IL, Cd3, HSP, CD40L, Flt3)
  • Microbe-derived immunostimulants (TLR agonists, MRL, MDP, CpG)
  • Particulate immunostimulants (VLPs, oil-in-water, PLGA)
  • Mucosal/non-parenteral adjuvants (CT/LT, CpG, T and B cell (stimulating) adjuvants (for TB, Malaria, HIV, Influenza))
  • Pharmaceutical adjuvant technology (synthetic molecules, immiquimod, lipid A)
  • Adjuvants in non-infectious disease vaccines (anti-fertility, anti-autoimmunity, anti-allergy, anti-obesity, anti-cancer)
  • Pharmaceutical aspects
  • Regulatory/licensing issues for immunopotentiators
  • Safety issues for immunopotentiators

Special Poster Session

IMV 2014 will include a special poster session, where selected poster paper authors will be invited to make short oral presentations of their poster paper to the IMV 2014 audience. Further details will be given on formal acceptance for POSTER presentation.


IMV 2014 Delegates

Login details will be supplied after you have registered for the event.

IMV 2014 Sponsors

  • Viscogel
  • Inovio Pharmaceuticals
  • Infectious Disease Research Institute
  • Brenntag
  • Sanofi Pasteur
  • Univac
  • Abivax
  • Immune Design
  • Seppic
  • Mucosis
  • NatureGeneTherapy
  • Dynavax Technologies
  • Eurocine Vaccines
  • Novartis Vaccines
  • European Adjuvant Advisory Committee
  • Aldevron
  • Pfizer

IMV 2014 Downloads

IMV 2014 Leaflet

IMV 2014 Mailing List

E-mail Address
What is 2+6-2?